Advertisement

Topics

Latest "Prolysis Limited" News Stories

05:32 EDT 18th October 2017 | BioPortfolio

Here are the most relevant search results for "Prolysis Limited" found in our extensive news archives from over 250 global news sources.

More Information about Prolysis Limited on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Prolysis Limited for you to read. Along with our medical data and news we also list Prolysis Limited Clinical Trials, which are updated daily. BioPortfolio also has a large database of Prolysis Limited Companies for you to search.

Showing "Prolysis Limited" News Articles 1–25 of 327

Wednesday 18th October 2017

Dimerix Appoints Medical Advisory Board in Readiness for Phase 2b Trials

MELBOURNE, Australia - 18th October 2017 - Dimerix (ASX: DXB) is pleased to announce the appointment of a Medical Advisory Board (MAB) to help guide the Company’s DMX-200 clinical program. The Medical Advisory Board will provide clinical and strategic input into the Company’s lead program, DMX-200 in Chronic Kidney Disease and will provide guidance to the Company as it shapes and p...


Tuesday 17th October 2017

Terveystalo Plc's ten largest shareholders after the completion of the Initial Public Offering

TERVEYSTALO PLC            STOCK EXCHANGE RELEASE           October 17, 2017 at 2:30 p.m. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA, JAPAN, SOUTH AFRICA OR THE UNITED STATES, OR ANY OTHER JURISDICTIO...

TTP Plc and Sphere Fluidics introduce Cyto-Mine Single Cell Analysis System.

A novel and disruptive analysis and monoclonal assurance system for drug discovery and development Cambridge, UK, 17 October 2017: TTP Plc (TTP), a leading independent technology and product development company, and Sphere Fluidics, which provides single cell analysis systems underpinned by its patented picodroplet technology, today announced the launch of the Cyto-Mine® Single Cell An...


Monday 16th October 2017

Cannabis Wheaton Provides Initial Advance of $5,000,000 to Beleave

VANCOUVER, BC--(Marketwired - October 17, 2017) - Cannabis Wheaton Income Corp. (TSX VENTURE: CBW) ("Cannabis Wheaton"or"CBW") and Beleave Inc. (CSE: BE) (OTCQX: BLEVF) ("Beleave" or the "Company") are pleased to announce that, further to the news release dated October 5, 2017, CBW has provided an initial advance of $5,000,000 in non-dilutive debt financing by way of an instrument evidencing a de...

REPEAT - Cannabis Wheaton Provides Initial Advance of $5,000,000 to Beleave

VANCOUVER, BC--(Marketwired - October 17, 2017) - Cannabis Wheaton Income Corp. (TSX VENTURE: CBW) ("Cannabis Wheaton"or"CBW") and Beleave Inc. (CSE: BE) (OTCQX: BLEVF) ("Beleave" or the "Company") are pleased to announce that, further to the news release dated October 5, 2017, CBW has provided an initial advance of $5,000,000 in non-dilutive debt financing by way of an instrument evidencing a de...

Corbus Pharmaceuticals Appoints Paris Panayiotopoulos to Its Board of Directors

NORWOOD, MA--(Marketwired - October 17, 2017) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that it has appointed Mr. Paris Panayiotopoulos to its Board of Directors. Mr. Panayiotopoulos was most recently the President and Chief Execu...

VBI Vaccines Hepatitis B Data Selected as Presidential Poster of Distinction at The Liver Meeting(R) 2017

CAMBRIDGE, MASSACHUSETTS -- (Marketwired) -- 10/17/17 -- VBI Vaccines Inc. (NASDAQ: VBIV)(TSX: VBV) (VBI) today announced the company's abstract, "Antibody and Cell-mediated Immunity against PreS1, PreS2, and S Antigens after Immunizations with a Third Generation Hepatitis B Vaccine," has been selected as a Presidential Poster of Distinction for presentation at the 68th annual meeting of the Ame...

CannaRoyalty Commends Favourable CSA Notice Regarding Issuers with U.S. Marijuana-Related Activities

OTTAWA, ONTARIO -- (Marketwired) -- 10/17/17 -- CannaRoyalty Corp. (CSE: CRZ)(CSE: CRZ.CN)(CNSX: CRZ)(OTCQX: CNNRF) ("CannaRoyalty" or the "Company"), an active investor and operator in the legal cannabis industry, commented on Canadian Securities Administrators ("CSA") Staff Notice 51-352, Issuers with U.S. Marijuana-Related Activities (the "Notice"). "With this Notice, the CSA has removed unc...

Quotient Limited to Report Fiscal Second Quarter 2018 Financial Results and Host Conference Call

JERSEY, Channel Islands, Oct. 17, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal second quarter ended September 30, 2017, will be released after market close on Monday, October 30, 2017. Quotient will host a conference call on Tuesday, October 31, 2017 at 8:30 a.m. Eastern Time to discu...

Thursday 12th October 2017

Global Cardiometabolic Monitoring Market Research Report Forecast 20172022 [Report Updated: 18092017] Prices from USD $2800

Delivery of the Report will take 4872 hours once order is placed.The Global Cardiometabolic Monitoring Market Research Report Forecast 20172022 is a valuable source of insightful data for business strategists. It provides the Cardiometabolic Monitoring industry overview with growth analysis and historical futuristic cost, revenue, demand and supply data as applicable. The research analysts provid...

Fagron: Turnover growth supported by key regions Europe, South America and North America

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands)1, 12 October 2017 Key points Turnover increases to € 103.6 million Organic turnover growth at constant exchange rates of 2.4% Active buy-and-build strategy: Acquisition of Croatian Kemig in August Acquisition of Brazilian All

Wednesday 11th October 2017

Applying ICH GCP E6(R2) Guidelines to All Aspects of Clinical Trials

TORONTO, ON and CHAPEL HILL, NC--(Marketwired - October 12, 2017) - In a live broadcast taking place on Monday, October 30, 2017 at 12pm EDT industry expert CROS NT (a data-driven CRO) will host a Webinar to explain how to apply ICH GCP E6(R2) guidelines to all aspects of clinical trials. It will cover how to meet ICH E6(R2) Guidelines, enable Risk-Based Monitoring, increase Sponsor's oversight o...

InspireMD Announces Distribution Agreement for MGuard Prime(TM) in Chile

TEL AVIV, ISRAEL -- (Marketwired) -- 10/12/17 -- InspireMD, Inc. (NYSE American: NSPR) (NYSE MKT: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it has signed an agreement with CorpMedical Chile Ltda, a leading medical distributor in Chile, with its headquarters in Santiago de Chile, to distribute the MGuard Prime...

Tuesday 10th October 2017

Trillium Therapeutics Welcomes Dr. Helen Tayton-Martin to Its Board of Directors

TORONTO, ONTARIO -- (Marketwired) -- 10/11/17 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that Dr. Helen Tayton-Martin has been appointed to its board of directors. Dr. Tayton-Martin, Chief Business Officer at Adaptimmune, has over 25 years of experience working wit...

VBI Vaccines to Present at The World Vaccine Congress Europe 2017 in Barcelona

CAMBRIDGE, MASSACHUSETTS -- (Marketwired) -- 10/11/17 -- VBI Vaccines Inc. (NASDAQ: VBIV)(TSX: VBV) (VBI) today announced that Adam Buckley, vice president of business development, will discuss VBI's enveloped virus-like particle (eVLP) platform, highlighting data from two of the company's vaccine programs, during a presentation at the World Vaccine Congress Europe held Oct. 10-12, 2017, in Barc...

The IPO of Terveystalo Plc has been oversubscribed and the listing will be completed as planned

TERVEYSTALO PLC STOCK EXCHANGE RELEASE October 10, 2017 at 3:00 p.m. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA, JAPAN, SOUTH AFRICA OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATI...

Abiomed Second Quarter Fiscal 2018 Earnings and Conference Call Notification

DANVERS, Mass., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD) announced that on Thursday, October 26, 2017, the Company will release financial results for the second quarter of fiscal 2018. The Company will host a conference call to discuss the results on Thursday, October 26, 2017, at 8:00 a.m. EDT. Michael R. Minogue, Chairman, President and Chief Executive Officer and Rob...

Optibrium Joins EUR 40 Million eTRANSAFE project

Prestigious line-up of pharma, academia and SMEs aim to improve security in drug development process CAMBRIDGE, UK, 10 October 2017 – Optibrium™, a developer of software for small molecule drug discovery, today announced that it will join the Enhancing Translational Safety Assessment through Integrative Knowledge Management (eTRANSAFE) project. eTRANSAFE is a five-year, 40 mill...

Monday 9th October 2017

Knight Increases Ownership in Crescita

MONTREAL, QUEBEC -- (Marketwired) -- 10/10/17 -- Pursuant to the early warning requirements of National Instrument 62-103, Knight Therapeutics Inc. (TSX: GUD) ("Knight") announced today an increase in its ownership of Crescita Therapeutics Inc. ("Crescita"). On October 6, 2017, Knight acquired 566,471 common shares of Crescita, representing 4.0% of the issued and outstanding common shares of Cr...

Aequus Granted Chinese Patent for Once-Weekly Transdermal Aripiprazole

VANCOUVER, BC--(Marketwired - October 10, 2017) - Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today that the State Intellectual Property Office of the People's Republic of China (SIPO) has granted a Chinese patent for Aequus' once...

Terveystalo Plc announces the early close of the Institutional Offering due to oversubscription

TERVEYSTALO PLC            STOCK EXCHANGE RELEASE           October 9, 2017 at 6:00 pm NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA, JAPAN, SOUTH AFRICA OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN...

Vistin Pharma ASA : Proposal for Extraordinary Dividend

Oslo, Norway, 9 October 2017 Norwegian pharmaceutical company Vistin Pharma ASA ("Vistin Pharma") announced today that the Board of Vistin Pharma will propose an extraordinary dividend of NOK 7.00 per share. On 2 October, the Company announced the successful completion of the sale of its opioids and tablet manufacturing business to TPI Enterprises Limited, which resulted in t...

Sunday 8th October 2017

HCi Viocare Appoints Dr. John Doupis, MD, PhD to its Scientific Advisory Board

GLASGOW, SCOTLAND -- (Marketwired) -- 10/09/17 -- HCi Viocare ("the Company" (OTCQB: VICA)) is delighted to welcome Dr. John Doupis, MD, PhD to its team. Dr. Doupis joins the Scientific Advisory Board assuming the role of Director of Clinical Matters and Diabetes. Dr. Doupis is a former Clinical Research Fellow of the Joslin Diabetes Center, Harvard Medical School, in Boston, MA, USA, and Scient...

International Stem Cell Corporation Developed 3D Bioprinting Technology Targeted to Treat Liver Diseases

CARLSBAD, CA -- (Marketwired) -- 10/09/17 -- International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company that develops novel stem cell-based therapies and biomedical products, announced today a significant advancement in 3D bioprinting of liver tissue. ISCO's R&D team has developed a 3D b...

GeoVax Chief Scientific Officer to Deliver Two Talks at World Vaccine Congress

ATLANTA, GA -- (Marketwired) -- 10/09/17 -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced that its Chief Scientific Officer, Farshad Guirakhoo, PhD, will deliver two talks during the World Vaccine Congress Europe in Barcelona on October 11 and 12. Dr. Guirakhoo's first presentation on October 11 is entitled "Use of MVA-VLP Platform for Development ...


Quick Search
Advertisement
 

News Quicklinks